Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: Findings and recommendations

Kevin Watanabe-Smith, Jamila Godil, Anupriya Agarwal, Cristina Tognon, Brian Druker

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The identification and functional validation of potentially oncogenic mutations in leukemia is an essential step toward a future of personalized targeted therapy. To assess the oncogenic capacity of individual mutations, reliable and scalable in vitro experimental approaches are required. Since 1988, researchers have used the IL-3 dependent Ba/F3 transformation assay to validate the oncogenic potential of mutations to drive factor-independent growth. Here we report a previously unrecognized phenomenon whereby Ba/F3 cells, engineered to express weakly transforming mutations, present with additional acquired mutations in the expressed transgene following factor withdrawal. Using four mutations with known transformative capacity in three cytokine receptors (CSF2RB, CSF3R and IL7R), we demonstrate that the mutated receptors are highly susceptible to acquiring additional mutations. These acquired mutations of unknown functional significance are selected by factor withdrawal but appear to exist prior to the removal of growth factor. This anomaly has the potential to confound efforts to both validate and characterize oncogenic mutations in leukemia, particularly when it is not standard practice to sequence validate cDNAs from transformed Ba/F3 lines. We present specific recommendations to detect and mitigate this phenomenon in future research using Ba/F3 transformation assays, along with methods to make the Ba/F3 assay more quantitative.

Original languageEnglish (US)
Pages (from-to)12596-12606
Number of pages11
JournalOncotarget
Volume8
Issue number8
DOIs
StatePublished - 2017

Fingerprint

Transgenes
Mutation
Intercellular Signaling Peptides and Proteins
Leukemia
Cytokine Receptors
Interleukin-3
Complementary DNA
Research Personnel

Keywords

  • Ba/F3 transformation assay
  • Functional validation
  • Leukemia
  • Oncogenes
  • Reproducibility in research

ASJC Scopus subject areas

  • Oncology

Cite this

Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays : Findings and recommendations. / Watanabe-Smith, Kevin; Godil, Jamila; Agarwal, Anupriya; Tognon, Cristina; Druker, Brian.

In: Oncotarget, Vol. 8, No. 8, 2017, p. 12596-12606.

Research output: Contribution to journalArticle

@article{2a805d38669a482db010f1e1aa09011b,
title = "Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: Findings and recommendations",
abstract = "The identification and functional validation of potentially oncogenic mutations in leukemia is an essential step toward a future of personalized targeted therapy. To assess the oncogenic capacity of individual mutations, reliable and scalable in vitro experimental approaches are required. Since 1988, researchers have used the IL-3 dependent Ba/F3 transformation assay to validate the oncogenic potential of mutations to drive factor-independent growth. Here we report a previously unrecognized phenomenon whereby Ba/F3 cells, engineered to express weakly transforming mutations, present with additional acquired mutations in the expressed transgene following factor withdrawal. Using four mutations with known transformative capacity in three cytokine receptors (CSF2RB, CSF3R and IL7R), we demonstrate that the mutated receptors are highly susceptible to acquiring additional mutations. These acquired mutations of unknown functional significance are selected by factor withdrawal but appear to exist prior to the removal of growth factor. This anomaly has the potential to confound efforts to both validate and characterize oncogenic mutations in leukemia, particularly when it is not standard practice to sequence validate cDNAs from transformed Ba/F3 lines. We present specific recommendations to detect and mitigate this phenomenon in future research using Ba/F3 transformation assays, along with methods to make the Ba/F3 assay more quantitative.",
keywords = "Ba/F3 transformation assay, Functional validation, Leukemia, Oncogenes, Reproducibility in research",
author = "Kevin Watanabe-Smith and Jamila Godil and Anupriya Agarwal and Cristina Tognon and Brian Druker",
year = "2017",
doi = "10.18632/oncotarget.15392",
language = "English (US)",
volume = "8",
pages = "12596--12606",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "8",

}

TY - JOUR

T1 - Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays

T2 - Findings and recommendations

AU - Watanabe-Smith, Kevin

AU - Godil, Jamila

AU - Agarwal, Anupriya

AU - Tognon, Cristina

AU - Druker, Brian

PY - 2017

Y1 - 2017

N2 - The identification and functional validation of potentially oncogenic mutations in leukemia is an essential step toward a future of personalized targeted therapy. To assess the oncogenic capacity of individual mutations, reliable and scalable in vitro experimental approaches are required. Since 1988, researchers have used the IL-3 dependent Ba/F3 transformation assay to validate the oncogenic potential of mutations to drive factor-independent growth. Here we report a previously unrecognized phenomenon whereby Ba/F3 cells, engineered to express weakly transforming mutations, present with additional acquired mutations in the expressed transgene following factor withdrawal. Using four mutations with known transformative capacity in three cytokine receptors (CSF2RB, CSF3R and IL7R), we demonstrate that the mutated receptors are highly susceptible to acquiring additional mutations. These acquired mutations of unknown functional significance are selected by factor withdrawal but appear to exist prior to the removal of growth factor. This anomaly has the potential to confound efforts to both validate and characterize oncogenic mutations in leukemia, particularly when it is not standard practice to sequence validate cDNAs from transformed Ba/F3 lines. We present specific recommendations to detect and mitigate this phenomenon in future research using Ba/F3 transformation assays, along with methods to make the Ba/F3 assay more quantitative.

AB - The identification and functional validation of potentially oncogenic mutations in leukemia is an essential step toward a future of personalized targeted therapy. To assess the oncogenic capacity of individual mutations, reliable and scalable in vitro experimental approaches are required. Since 1988, researchers have used the IL-3 dependent Ba/F3 transformation assay to validate the oncogenic potential of mutations to drive factor-independent growth. Here we report a previously unrecognized phenomenon whereby Ba/F3 cells, engineered to express weakly transforming mutations, present with additional acquired mutations in the expressed transgene following factor withdrawal. Using four mutations with known transformative capacity in three cytokine receptors (CSF2RB, CSF3R and IL7R), we demonstrate that the mutated receptors are highly susceptible to acquiring additional mutations. These acquired mutations of unknown functional significance are selected by factor withdrawal but appear to exist prior to the removal of growth factor. This anomaly has the potential to confound efforts to both validate and characterize oncogenic mutations in leukemia, particularly when it is not standard practice to sequence validate cDNAs from transformed Ba/F3 lines. We present specific recommendations to detect and mitigate this phenomenon in future research using Ba/F3 transformation assays, along with methods to make the Ba/F3 assay more quantitative.

KW - Ba/F3 transformation assay

KW - Functional validation

KW - Leukemia

KW - Oncogenes

KW - Reproducibility in research

UR - http://www.scopus.com/inward/record.url?scp=85013486070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013486070&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.15392

DO - 10.18632/oncotarget.15392

M3 - Article

C2 - 28208123

AN - SCOPUS:85013486070

VL - 8

SP - 12596

EP - 12606

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 8

ER -